- Home
- S vs AXSM Comparison
S vs AXSM Comparison
Compare S & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- S
- AXSM
- Stock Information
- Founded
- S 2013
- AXSM 2012
- Country
- S United States
- AXSM United States
- Employees
- S N/A
- AXSM N/A
- Industry
- S EDP Services
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- S Technology
- AXSM Health Care
- Exchange
- S Nasdaq
- AXSM Nasdaq
- Market Cap
- S 6.2B
- AXSM 5.1B
- IPO Year
- S 2021
- AXSM 2015
- Fundamental
- Price
- S $17.24
- AXSM $107.56
- Analyst Decision
- S Buy
- AXSM Strong Buy
- Analyst Count
- S 30
- AXSM 15
- Target Price
- S $24.77
- AXSM $170.20
- AVG Volume (30 Days)
- S 5.4M
- AXSM 612.2K
- Earning Date
- S 05-28-2025
- AXSM 05-05-2025
- Dividend Yield
- S N/A
- AXSM N/A
- EPS Growth
- S N/A
- AXSM N/A
- EPS
- S N/A
- AXSM N/A
- Revenue
- S $864,135,000.00
- AXSM $432,157,000.00
- Revenue This Year
- S $25.63
- AXSM $63.30
- Revenue Next Year
- S $22.00
- AXSM $61.15
- P/E Ratio
- S N/A
- AXSM N/A
- Revenue Growth
- S 28.19
- AXSM 72.16
- 52 Week Low
- S $14.33
- AXSM $64.11
- 52 Week High
- S $29.29
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- S 34.67
- AXSM 50.87
- Support Level
- S $16.80
- AXSM $101.41
- Resistance Level
- S $20.29
- AXSM $106.77
- Average True Range (ATR)
- S 0.54
- AXSM 3.01
- MACD
- S -0.34
- AXSM 0.01
- Stochastic Oscillator
- S 9.21
- AXSM 67.83
About S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.